Across all study participants, 34.4% of those treated with FB102 reached FVASI50 and 12.5% attained FVASI75 at week 24.
Niagen Bioscience (NAGE) is expected to deliver flat earnings compared to the year-ago quarter on higher revenues when it reports results for the quarter ended September 2025. This widely-known ...
A live webcast will be held on Wednesday, May 6, 2026, at 4:30 p.m. Eastern Daylight Time (1:30 p.m. Pacific Daylight Time) to discuss Niagen Bioscience’s first quarter financial results and provide a ...
View source version on businesswire.com: https://www.businesswire.com/news/home/20260615772156/en/ The articles, information, and content displayed on this webpage ...
Twist Bioscience (TWST) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2025. This widely-known consensus outlook ...
Single dose of CB-011 produced deep, durable responses in heavily pretreated, BCMA-naïve patients with r/r MM: 83% CR rate, 91% MRD ...
The conference call will be broadcast live and available for replay via the investor relations section of the Company’s website at www.niagenbioscience.com. The replay of the conference call will be ...
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report second quarter 2025 financial results on Tuesday, August 5, 2025, before ...
PURE Bioscience, Inc. ( OTCQB: PURE ) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate ( SDC ) antimicrobial, today reported financial results for the ...
Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that it will hold a conference ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results